Article
Side Chain-modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity
2023-06-01
Abstract excerpt
Tuberculosis (TB) is a leading infectious disease with serious antibiotic resistance. The benzothiazinone (BTZ) scaffold PBTZ169, an inhibitor of the decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1) in Mycobacterium tuberculosis (Mtb), showed anti-TB potential in animal model and piloted clinical tests. Although highly potent, the BTZ type DprE1 inhibitors in general shows extremely low aqueous solubility,...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 74007a55-4dbb-5bb9-9857-3d4b1904f126
- DOI
- 10.20944/preprints202305.1839.v2
